Equity Overview
Price & Market Data
Price: $14.30
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $383,490,240
Volume: 0
Performance Metrics
1 Week: -15.08%
1 Month: -16.47%
3 Months: -8.22%
6 Months: 18.77%
1 Year: 295.0%
YTD: 7.36%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.